Abstract
Gene delivery/expression vectors have been used as fundamental technologies in gene therapy since the 1980s. These technologies are also being applied in regenerative medicine as tools to reprogram cell genomes to a pluripotent state and to other cell lineages. Rapid progress in these new research areas and expectations for their translation into clinical applications have facilitated the development of more sophisticated gene delivery/expression technologies. Since its isolation in 1953 in Japan, Sendai virus (SeV) has been widely used as a research tool in cell biology and in industry, but the application of SeV as a recombinant viral vector has been investigated only recently. Recombinant SeV vectors have various unique characteristics, such as low pathogenicity, powerful capacity for gene expression and a wide host range. In addition, the cytoplasmic gene expression mediated by this vector is advantageous for applications, in that chromosomal integration of exogenous genes can be undesirable. In this review, we introduce a brief historical background on the development of recombinant SeV vectors and describe their current applications in gene therapy. We also describe the application of SeV vectors in advanced nuclear reprogramming and introduce a defective and persistent SeV vector (SeVdp) optimized for such reprogramming.
Keywords: Sendai virus, gene therapy, nuclear reprogramming, induced pluripotent stem cells (iPSCs), regenerative medicine, viral vectors, gene delivery vectors, DNA–carrier
Current Gene Therapy
Title:Development of Sendai Virus Vectors and their Potential Applications in Gene Therapy and Regenerative Medicine
Volume: 12 Issue: 5
Author(s): Mahito Nakanishi and Makoto Otsu
Affiliation:
Keywords: Sendai virus, gene therapy, nuclear reprogramming, induced pluripotent stem cells (iPSCs), regenerative medicine, viral vectors, gene delivery vectors, DNA–carrier
Abstract: Gene delivery/expression vectors have been used as fundamental technologies in gene therapy since the 1980s. These technologies are also being applied in regenerative medicine as tools to reprogram cell genomes to a pluripotent state and to other cell lineages. Rapid progress in these new research areas and expectations for their translation into clinical applications have facilitated the development of more sophisticated gene delivery/expression technologies. Since its isolation in 1953 in Japan, Sendai virus (SeV) has been widely used as a research tool in cell biology and in industry, but the application of SeV as a recombinant viral vector has been investigated only recently. Recombinant SeV vectors have various unique characteristics, such as low pathogenicity, powerful capacity for gene expression and a wide host range. In addition, the cytoplasmic gene expression mediated by this vector is advantageous for applications, in that chromosomal integration of exogenous genes can be undesirable. In this review, we introduce a brief historical background on the development of recombinant SeV vectors and describe their current applications in gene therapy. We also describe the application of SeV vectors in advanced nuclear reprogramming and introduce a defective and persistent SeV vector (SeVdp) optimized for such reprogramming.
Export Options
About this article
Cite this article as:
Nakanishi Mahito and Otsu Makoto, Development of Sendai Virus Vectors and their Potential Applications in Gene Therapy and Regenerative Medicine, Current Gene Therapy 2012; 12 (5) . https://dx.doi.org/10.2174/156652312802762518
DOI https://dx.doi.org/10.2174/156652312802762518 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Mechanisms of Tubulin Binding Ligands to Target Cancer Cells: Updates on their Therapeutic Potential and Clinical Trials
Current Cancer Drug Targets Potential of Taming MicroRNA on Driver Seat to Control Mitochondrial Horses in Breast Carcinoma
MicroRNA An Update on the Other Telomerase Inhibitors: Non-G-Quadruplex Interactive Agent, Non-Antisense, Non-Reverse Transcriptase Telomerase Inhibitors
Medicinal Chemistry Reviews - Online (Discontinued) Recent Advances in the Design and Synthesis of Small Molecule Carbonic Anhydrase IX Inhibitors
Current Topics in Medicinal Chemistry The Potential Therapeutic Role of the HMGB1-TLR Pathway in Epilepsy
Current Drug Targets Rediscovering Tocophersolan: A Renaissance for Nano-Based Drug Delivery and Nanotheranostic Applications
Current Drug Targets Current Targeting Strategies for Adenovirus Vectors in Cancer Gene Therapy
Current Cancer Drug Targets Hypericin Lights Up the Way for the Potential Treatment of Nasopharyngeal Cancer by Photodynamic Therapy
Current Clinical Pharmacology Membrane Transporters as Determinants of the Pharmacology of Platinum Anticancer Drugs
Current Cancer Drug Targets To Seek Shelter from the Wnt in Osteoarthritis? Wnt-Signaling as a Target for Osteoarthritis Therapy
Current Drug Targets Applications of Nanocarbons in Bio-Medical Devices
Recent Innovations in Chemical Engineering Anticancer Therapeutic Strategies Based on CDK Inhibitors
Current Pharmaceutical Design Tumor Control by Manipulation of the Human Anti-Apoptotic Survivin Gene
Current Cancer Therapy Reviews Tailored Angiogenesis Inhibition in Cancer Therapy: Respecting the Heart to Improve the Net Outcome
Current Signal Transduction Therapy Form and Function in Cyclic Peptide Natural Products: A Pharmacokinetic Perspective
Current Topics in Medicinal Chemistry Asbestos-Related Diseases: Still a Concern in Emerging Economies in the Absence of an International Ban
Current Respiratory Medicine Reviews TGF-Beta Type I Receptor (Alk5) Kinase Inhibitors in Oncology
Current Pharmaceutical Biotechnology Targeting Neuronal Nicotinic Receptors in Cancer: New Ligands and Potential Side-Effects
Recent Patents on Anti-Cancer Drug Discovery TEM8 Targeted Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Comprehensive Analysis Reveals GPRIN1 is a Potential Biomarker for Non-sm all Cell Lung Cancer
Current Bioinformatics